What it is
Neuropeptide Y is a chain of 36 amino acids used as a signal by nerve cells. UniProt's record for the human gene (P01303, read 2026-11-13) shows a 97-residue precursor: a 28-residue signal piece, then the 36-residue peptide, then a 30-residue leftover called the C-flanking peptide of NPY.
It was first reported in Nature in 1982 by Tatemoto and colleagues, under the title "Neuropeptide Y — a novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide" (PMID 6896083). That title names its family: three related 36-residue peptides. The gut member is described in the peptide YY entry.
| Property | Value | Source |
|---|---|---|
| Length | 36 amino acids | UniProt P01303 |
| Human sequence | YPSKPDNPGEDAPAEDMARYYSALRHYINLITRQRY | UniProt P01303, residues 29–64 |
| Precursor | 97 residues | UniProt P01303 |
| First described | 1982, as a brain peptide | Tatemoto et al., PMID 6896083 |
A note on the database formula. PubChem's record under the name "neuropeptide Y" (CID 16132350) gives C190H287N55O57 — a formula with no sulfur. The human sequence above contains one methionine, which carries a sulfur atom. So that record cannot be the human peptide; it must describe a form with a different amino acid at that position (our reading of the formula against the sequence, not a statement from PubChem). Molecular weights quoted from that record, about 4,254, are therefore not the human figure.
What it is said to do
Reviews in the field describe NPY as a source of "resilience" against stress, and that word has travelled into wellness writing. The research behind it splits cleanly by species.
| Kind of study | What was reported | Record |
|---|---|---|
| Rats, stress model | NPY through the nose before or after a stress procedure reduced anxiety-like and depression-like behaviour | Serova et al. 2014 (PMID 24326087) |
| Rats | Without stress, no behavioural change a week after one nasal dose; given at the time of stress, it prevented the stress-linked loss of fear extinction | Sabban et al. 2023 (PMID 37157881) |
| Rodents, pain models | NPY signalling restrains chronic pain after injury | Review, 2025 (PMID 40754889) |
| People with PTSD | Single nasal doses; dose-related effect on one of two anxiety scales | Sayed et al. 2018 (PMID 29186416) |
| People with depression | One nasal dose; better than placebo at 24 hours, not at the 48-hour primary endpoint | Mathé et al. 2020 (PMID 33009815) |
The two human trials, read closely
The PTSD trial (Sayed et al. 2018; registered as NCT01533519) is a dose-ranging safety study, not a test of a treatment.
- 26 people with post-traumatic stress disorder were randomised; 24 completed both treatment days.
- Each person received one dose of NPY and one of placebo, a week apart, in random order.
- Five dose groups of 3 to 6 people each, from 1.4 mg to 9.6 mg — figures reported from the trial, not guidance.
- NPY "was well tolerated up to and including the highest dose."
- On the Beck Anxiety Inventory, higher doses were associated with a greater effect favouring NPY (P=.038). On the second scale the abstract reports no significant interaction.
The depression trial (Mathé et al. 2020; EudraCT 2014-000129-19) is the larger of the two.
- 30 patients with major depressive disorder, all on a stable antidepressant, were randomised: 12 received one 6.8 mg dose of NPY through the nose and 18 received placebo.
- The planned main result was the change in a depression score at 48 hours. That difference "was not significant."
- At 24 hours the score had fallen by 10.3 points on NPY and 5.6 on placebo (P=.04) — a difference of 4.7 points by our subtraction. This was a secondary measure.
- The authors conclude that NPY "is antidepressant, despite not meeting the primary outcome", and call for trials with repeated doses.
Set side by side: one trial positive on one of two scales in groups of six or fewer, the other positive on a secondary time point and negative on its primary one, both after a single dose. That is a signal worth larger trials, and no more. A 2026 review by researchers in this field says the peptide's "therapeutic potential has not yet been realized" (PMID 41818915).
What is registered
ClinicalTrials.gov returned 100 studies mentioning neuropeptide Y and 17 when NPY is searched as an intervention (2026-11-13). Reading those 17, most only measure NPY in blood or tissue. Five give the peptide:
| Record | What it is | Enrolment | Status |
|---|---|---|---|
| NCT00748956 | Nasal NPY in healthy men | 10 | Completed |
| NCT01533519 | Dose escalation in PTSD (the trial above) | 26 | Completed |
| NCT02639637 | NPY as a probe of blood-vessel narrowing | 18 | Completed |
| NCT04071600 | Nasal NPY in trauma patients | 117 planned | Status unknown |
| NCT04838678 | NPY as a probe in obesity-related hypertension | 100 planned | Recruiting |
The two largest are a study whose status the registry lists as unknown and one still recruiting; neither has posted results.
What is not established
- That NPY treats anxiety, PTSD, depression or pain in people. Both patient trials gave a single dose, and the depression trial missed its primary endpoint.
- Whether repeated dosing is safe or effective. The two published patient trials gave single doses, and the 2020 authors themselves call for repeated-dose trials.
- How much of a nasal dose reaches the brain in people.
- Anything about products sold as NPY. Research-vendor listings are not a source for this library.
Where it stands
- Approved: no.
- Human trials giving the peptide: five registered, by this entry's reading.
- Research record: PubMed 6,413 title records; 131 records tagged as randomised controlled trials mention it (2026-11-13).
Related reading
NPY-producing nerve cells in the hypothalamus are among the targets of ghrelin, the stomach's hunger hormone; a second appetite signal is described in the leptin entry. Another brain peptide tied to appetite and wakefulness is covered in the orexin entry. For peptides marketed for stress and mood, with their evidence set side by side, see the focus-and-mood overview.
